OncoZenge AB (ONCOZ) AI Stock Analysis

• Market Cap: kr77.02M
• Dividend Yield: N/A
• Average Volume (3M): 32.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.99
• Revenue Growth: N/A
• EPS Growth: 20.55%
• Country: SE
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 12,647,174
• 10 Day Avg. Volume: 40,755
• 30 Day Avg. Volume: 32,639
• PEG Ratio: 0.11
• Price to Book (P/B): 4.41
• Price to Sales (P/S): 43924.69
• P/FCF Ratio: -5.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -7.5
• Revenue Forecast (FY): kr28.13M

• Rating: 41 Neutral
• Price Target: ―

OncoZenge AB faces substantial financial hurdles, with key weaknesses in profitability and cash flow, which are critical for the company's future viability. Technical analysis indicates bearish momentum, further exacerbating the company's challenges. Valuation metrics reflect its current unprofitability, offering little incentive for investors. Without significant strategic changes, the company's financial health remains precarious.

OncoZenge AB Business Overview & Revenue Model

Company Description

OncoZenge AB is a Swedish pharmaceutical company focused on the development and commercialization of innovative treatments for cancer. Leveraging advanced research in oncology, the company aims to address unmet medical needs by offering novel therapeutic solutions that improve patient outcomes. OncoZenge operates within the biotechnology and pharmaceutical sectors, concentrating on the development of proprietary drug formulations and delivery systems designed to enhance the efficacy and safety of cancer therapies.

How the Company Makes Money

OncoZenge AB generates revenue primarily through the development and commercialization of its proprietary cancer treatments. The company may earn income from licensing agreements with other pharmaceutical companies, allowing them to market and distribute OncoZenge's products in various regions. Additionally, OncoZenge might engage in partnerships or collaborations with research institutions and industry peers to co-develop new therapies, potentially leading to shared revenues. The company may also seek funding through grants, research subsidies, or investment from private and public sources to support its research and development activities.

OncoZenge AB Financial Statement Overview

Summary

OncoZenge AB is facing significant financial challenges, particularly in terms of profitability and cash flow. The company's strong equity position and lack of debt provide some buffer, but persistent losses and declining revenues highlight the need for strategic adjustments to improve financial performance and ensure long-term viability.

Income Statement

OncoZenge AB has struggled with profitability, consistently reporting negative net income and EBIT margins, indicative of high operating expenses relative to revenue. Revenue growth was negative, as total revenue declined significantly from 2023 to 2024. The company has a high gross profit margin, but this is overshadowed by substantial losses.

Balance Sheet

The company maintains a strong equity position, with no debt and a high equity ratio at 86.98% in 2024. However, the return on equity is negative due to consistent net losses. The financial stability is supported by substantial cash reserves, but the ongoing losses could pose a risk to long-term sustainability if not addressed.

Cash Flow

Operating cash flow remains negative, reflecting challenges in generating cash from operations. The free cash flow has deteriorated, indicating potential liquidity issues. The ratios of operating and free cash flow to net income are unfavorable, underscoring inefficiencies in cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.66M	1.00K	3.00K	0.00	0.00	0.00
Gross Profit	5.66M	1.00K	3.00K	0.00	0.00	0.00
EBITDA	-24.04M	-8.69M	7.27M	2.77M	-4.89M	-801.00K
Net Income	-24.09M	-8.69M	-15.90M	-46.65M	-3.89M	-636.00K
Balance Sheet
Total Assets	19.84M	11.43M	20.34M	36.89M	85.23M	38.30M
Cash, Cash Equivalents and Short-Term Investments	11.59M	3.86M	12.63M	29.14M	51.22M	10.00M
Total Debt	7.50M	0.00	0.00	0.00	0.00	0.00
Total Liabilities	10.53M	1.48M	1.70M	2.92M	4.90M	9.01M
Stockholders Equity	9.30M	9.95M	18.64M	33.97M	80.32M	29.28M
Cash Flow
Free Cash Flow	-22.59M	-8.76M	-17.08M	-22.08M	-10.12M	-1.00K
Operating Cash Flow	-22.59M	-8.76M	-17.08M	-22.08M	-4.77M	-1.00K
Investing Cash Flow	0.00	0.00	570.00K	0.00	-5.36M	0.00
Financing Cash Flow	54.17M	0.00	0.00	0.00	51.34M	10.00M

OncoZenge AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.51
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ONCOZ, the sentiment is Neutral. The current price of 5.51 is below the 20-day moving average (MA) of 5.55, below the 50-day MA of 5.66, and below the 200-day MA of 5.85, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 49.07 is Neutral, neither overbought nor oversold. The STOCH value of 38.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ONCOZ.

OncoZenge AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MODTX	42 Neutral	€47.80M	-2.16	-166.94%	―	―	-19.35%
ONCOZ	41 Neutral	kr77.02M	―	-78.79%	―	―	20.55%
EXPRS2	41 Neutral	€56.06M	―	-88.65%	―	8.46%	11.73%
SPRINT	39 Underperform	€158.27M	―	-264.12%	―	-17.80%	-11.96%
LIDDS	37 Underperform	€7.78M	-1.40	-132.58%	―	―	86.26%